Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis

Supporting evidence

• Evaluation report

• Draft guidance consultation committee papers (PDF 17.7 MB)

  Published:

  24 July 2024

• Final draft guidance committee papers (PDF 6.05 MB)

  Published:

  24 July 2024